Rammohan, Kottil
Coyle, Patricia K.
Sylvester, Elke
Galazka, Andrew
Dangond, Fernando
Grosso, Megan
Leist, Thomas P.
Funding for this research was provided by:
EMD Serono, Inc.
Article History
First Online: 28 November 2020
Declarations
:
: Funding for writing and editorial support was provided by EMD Serono, Inc., Rockland, MA, USA, an affiliate of Merck KGaA, Darmstadt, Germany.
: Kottil Rammohan received honoraria for lectures and steering committee meetings from EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, Biogen, Sanofi-Aventis, Genzyme, Novartis, Teva Neurosciences, Acorda, and Roche/Genentech. Patricia K. Coyle received consultancy fees from Accordant, Actelion, Alexion, Bayer, Biogen, Celgene, Genentech/Roche, Novartis, Sanofi Genzyme, EMD Serono, Inc., an affiliate of Merk KGaA, Darmstadt, Germany, and TG Therapeutics, and also received research grants from Actelion Pharmaceuticals, Inc., Alkermes, Genentech/Roche, MedDay Pharmaceuticals, NINDS, and Novartis Pharmaceuticals. Elke Sylvester is an employee of Merck KGaA, Darmstadt, Germany. Andrew Galazka is an employee of Ares Trading SA, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany. Fernando Dangond is an employee of EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA, Darmstadt, Germany. Megan Grosso is an employee of EMD Serono, Inc., Rockland, MA, USA, an affiliate of Merck KGaA, Darmstadt, Germany. Thomas P. Leist received consultancy fees or clinical research grants from Alkermes, Bayer, Biogen, EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, Genentech, Genzyme, and Novartis.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: All authors contributed to the drafting of the manuscript and revising it critically for important intellectual content.